Políticas Médicas
Las políticas médicas son documentos que definen el reconocimiento de cubierta para tecnologías, procedimientos y tratamientos. Las declaraciones de necesidad médica en las políticas, sobre si una tecnología, procedimiento, tratamiento, suplido, equipo, medicamento u otro servicio mejora el resultado en la salud de la población para la cual dicha tecnología o tratamiento fue diseñado se basan en evidencia científica, estudios clínicos y opiniones profesionales de nuestros proveedores y de las organizaciones médicas reconocidas.
Cada documento desplegado en este sitio Web se provee con propósitos informativos solamente y no es una autorización, explicación de beneficios o un contrato. El recibir beneficios está sujeto a la satisfacción de todos los términos y condiciones de la cubierta. La tecnología médica cambia constantemente y nos reservamos el derecho de revisar y actualizar nuestras políticas periódicamente.
| ID | Título | Última Revisión | Siguiente Revisión | Descripción | Acceso |
|---|---|---|---|---|---|
| 11.003.028 | Genetic Testing For Lynch Syndrome And Other Inherited Colon Cancer Syndromes | Dec 05, 2024 | Oct 20, 2025 | Genetic testing is available for both those with and those at risk for various types of hereditary cancer.... | Ver |
| 11.003.029 | Epithelial Cell Cytology In Breast Cancer Risk Assesment And High-Risk Patient Management (Ductal Labage And Suction Collection Systems) | May 20, 2019 | Policy Archived | In summary, the available literature regarding ductal lavage and suction collection systems for breast cancer... | Ver |
| 11.003.030 | Genetic Testing For Brca1 Or Brca2 For Hereditary Breast/Ovarian Cancer Syndrome And Other High-Risk Cancers | Sep 19, 2025 | Sep 20, 2026 | Hereditary breast and ovarian cancer syndrome describes the familial cancer syndromes related to variants in... | Ver |
| 11.003.031 | Genetic Testing For Hereditary Hemochromatosis | Jun 10, 2025 | Policy Archived | Hereditary hemochromatosis (hh), a common genetic disorder of iron metabolism, can lead to inappropriate iron... | Ver |
| 11.003.032 | Analysis Of Human Dna In Stool Samples As A Technique For Colorectal Cancer Screening | Jan 20, 2025 | Jan 20, 2026 | Of safety and effectiveness data (ssed): cologuard. august 2014. accessed oct 21,... | Ver |
| 11.003.033 | Análisis de los patrones proteómicos séricos para identificar el cáncer de ovari | May 12, 2016 | Policy Archived | ... | Ver |
| 11.003.034 | Genetic And Protein Biomarkers For The Diagnosis And Cancer Risk Assessment Of Prostate Cancer | Dec 20, 2024 | Dec 20, 2025 | Various genetic and protein biomarkers are associated with prostate cancer. these tests have the potential to... | Ver |
| 11.003.035 | Assays Of Genetic Expression In Tumor Tissue As A Technique To Determine Prognosis In Patients With Breast Cancer | Dec 06, 2024 | Dec 20, 2025 | Laboratory tests have been developed to detect the expression, via messenger rna, of different genes in... | Ver |
| 11.003.036 | Genetic Testing For Familial Cutaneous Malignant Melanoma | Apr 18, 2025 | Apr 20, 2026 | Cutaneous melanoma is the third most common type of skin cancer, but the most lethal. some cases of cutaneous... | Ver |
| 11.003.037 | Novel Biomarkers In Risk Assessment And Management Of Cardiovascular Disease | Jan 20, 2025 | Jan 20, 2026 | Numerous lipid and non-lipid biomarkers have been proposed as potential risk markers for cardiovascular... | Ver |
| 11.003.038 | Biomarker Genes For Detection Of Lymph Node Metastases In Breast Cancer | May 15, 2019 | Policy Archived | As highlighted in a 2008 editorial, the ongoing difficulties with using molecular techniques to detect... | Ver |
| 11.003.039 | Pharmacogenomic And Metabolite Markers For Patients Treated With Thiopurines | Dec 20, 2024 | Dec 20, 2025 | The thiopurine class of drugs, which include azathioprine (a pro-drug for mercaptopurine), mercaptopurine,... | Ver |
| 11.003.040 | Genetic Testing For Alzheimer Disease | Nov 22, 2024 | Nov 20, 2025 | Alzheimer disease (ad) is the most common cause of dementia in elderly patients. for late-onset ad, there is... | Ver |
| 11.003.042 | Genetic Testing For Cardiac Ion Channelopathies | Feb 18, 2025 | Feb 20, 2026 | Genetic testing is available for patients suspected of having cardiac ion channelopathies, including long qt... | Ver |
| 11.003.046 | Genetic Testing For Fmr1 Variants (Including Fragile X Syndrome) | Feb 20, 2025 | Feb 20, 2026 | Fragile x syndrome (fxs) is the most common inherited form of mental disability and a known genetic cause of... | Ver |
| 11.003.047 | Gene Expression-Based Assays For Cancers Of Unknown Primary | May 09, 2025 | May 20, 2026 | Cancers of unknown primary represent 3% to 4% of cancers diagnosed in the united states. these cancers are... | Ver |
| 11.003.048 | Carrier Screening For Genetic Diseases | Oct 10, 2024 | Oct 20, 2025 | Carrier screening is performed to identify individuals at risk of having offspring with inherited recessive... | Ver |
| 11.003.049 | Genetic Testing For Diagnosis And Management Of Mental Health Conditions | Aug 18, 2025 | Aug 20, 2026 | Individual genes have been shown to be associated with the risk of psychiatric disorders and specific aspects... | Ver |
| 11.003.050 | Genetic Testing For Epilepsy | Apr 14, 2025 | Apr 20, 2026 | Epilepsy is a disorder characterized by unprovoked seizures. it is a heterogeneous condition that encompasses... | Ver |
| 11.003.051 | Gene Expression Profiling And Protein Biomarkers For Prostate Cancer Management | May 05, 2025 | May 20, 2026 | Gene expression profile analysis and protein biomarkers have been proposed as a means to risk-stratify... | Ver |
